UBXN1

Across TCGA pan-cancer cohorts, UBXN1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated UBXN1 data layer compared with 29 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher UBXN1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated UBXN1 expression acts as an unfavorable survival marker.

ACC, UCS, and STAD are the cancer types where UBXN1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.028	0.675	<.001	63	view →
UCS	DFS	Median	All	0.068	0.524	<.001	48	view →
STAD	OS	Median	II,III,IV	0.041	0.677	<.001	24	view →
LUAD	OS	Median	II,III,IV	0.111	0.750	<.001	24	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ESCA	DFS	Median	II,III,IV	0.149	0.522	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

UBXN1–ACC (DFS)

Open the ACC breakdown →